Shares of Aspen Aerogels Inc. (NYSE:ASPN) have been assigned a consensus recommendation of “Buy” from the seven brokerages that are presently covering the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $7.70.

ASPN has been the subject of several recent analyst reports. Canaccord Genuity reiterated a “buy” rating and issued a $8.50 target price on shares of Aspen Aerogels in a research note on Thursday, August 4th. Zacks Investment Research upgraded shares of Aspen Aerogels from a “sell” rating to a “hold” rating in a research note on Wednesday, October 5th. JPMorgan Chase & Co. reduced their target price on shares of Aspen Aerogels from $8.00 to $7.00 and set an “overweight” rating for the company in a research note on Friday, August 5th. Craig Hallum initiated coverage on shares of Aspen Aerogels in a research note on Tuesday, September 20th. They issued a “buy” rating and a $10.00 target price for the company. Finally, Citigroup Inc. reduced their target price on shares of Aspen Aerogels from $6.50 to $6.00 and set a “buy” rating for the company in a research note on Thursday, July 7th.

Shares of Aspen Aerogels (NYSE:ASPN) traded up 1.7250% during mid-day trading on Tuesday, reaching $6.2154. 22,411 shares of the company’s stock traded hands. Aspen Aerogels has a 12-month low of $3.38 and a 12-month high of $8.87. The company’s market cap is $127.93 million. The firm has a 50-day moving average of $5.27 and a 200 day moving average of $4.76.

Aspen Aerogels (NYSE:ASPN) last announced its quarterly earnings results on Thursday, August 4th. The company reported ($0.02) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.04) by $0.02. The business earned $27.70 million during the quarter, compared to analyst estimates of $30.99 million. Aspen Aerogels had a negative net margin of 3.14% and a negative return on equity of 3.35%. During the same quarter in the previous year, the business posted ($0.12) EPS. Equities analysts forecast that Aspen Aerogels will post ($0.31) EPS for the current year.

In related news, Director William P. Noglows purchased 20,000 shares of Aspen Aerogels stock in a transaction that occurred on Wednesday, August 24th. The stock was bought at an average price of $4.98 per share, for a total transaction of $99,600.00. Following the completion of the transaction, the director now owns 46,178 shares in the company, valued at $229,966.44. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Richard F. Reilly purchased 10,000 shares of Aspen Aerogels stock in a transaction that occurred on Tuesday, August 23rd. The shares were bought at an average price of $4.82 per share, with a total value of $48,200.00. Following the transaction, the director now owns 36,178 shares of the company’s stock, valued at approximately $174,377.96. The disclosure for this purchase can be found here. Corporate insiders own 14.70% of the company’s stock.

A number of institutional investors have recently bought and sold shares of ASPN. Reservoir Operations L.P. raised its position in Aspen Aerogels by 0.6% in the second quarter. Reservoir Operations L.P. now owns 2,916,103 shares of the company’s stock valued at $14,493,000 after buying an additional 18,451 shares during the last quarter. Ameriprise Financial Inc. raised its position in Aspen Aerogels by 12.9% in the second quarter. Ameriprise Financial Inc. now owns 872,629 shares of the company’s stock valued at $4,338,000 after buying an additional 99,600 shares during the last quarter. Tocqueville Asset Management L.P. raised its position in Aspen Aerogels by 35.1% in the second quarter. Tocqueville Asset Management L.P. now owns 657,080 shares of the company’s stock valued at $3,266,000 after buying an additional 170,650 shares during the last quarter. BlackRock Institutional Trust Company N.A. raised its position in Aspen Aerogels by 3.0% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 653,612 shares of the company’s stock valued at $3,248,000 after buying an additional 18,941 shares during the last quarter. Finally, Wall Street Associates raised its position in Aspen Aerogels by 28.8% in the second quarter. Wall Street Associates now owns 566,200 shares of the company’s stock valued at $2,814,000 after buying an additional 126,774 shares during the last quarter. Institutional investors own 76.10% of the company’s stock.

About Aspen Aerogels

Aspen Aerogels, Inc is an energy technology company that designs, develops and manufactures aerogel insulation used primarily in energy infrastructure facilities. The Company also performs contract research services for various federal and non-federal government agencies, including the Department of Defense, the Department of Energy and other institutions.

5 Day Chart for NYSE:ASPN

Receive News & Stock Ratings for Aspen Aerogels Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspen Aerogels Inc. and related stocks with our FREE daily email newsletter.